Biologic treatments for systemic rheumatic diseases

Abstract

Many rheumatologic disorders, most notably Sjögren’s syndrome, are associated with dental complications and in some cases oral diseases may trigger or drive connective tissue disease. During the past three decades the treatment in rheumatology was revolutionized by the introduction of disease-modifying anti-rheumatic drugs. Advances in our understanding of the pathogenesis of rheumatic diseases have led to the discovery of critical mechanisms of inflammation and autoimmunity and the invention of new target-specific biologic agents. In this review, we will summarize the current state of biologic therapies in rheumatology and discuss the implications of these on oral health and disease.

Introduction

Systemic rheumatic diseases are characterized by systemic autoimmunity leading to chronic inflammation in target organs and systems. Although the inciting event is not known for any of these conditions, it most likely results from a complex interaction of genetic, environmental and stochastic factors. A general model of pathogenesis is that in a genetically susceptible individual an initial breakdown in tolerance creates primary self-reactive cells, which then propagate the autoimmune response by a variety of mechanisms that include positive-feedback amplification loops, such as T and B lymphocyte activation, autoantibody production, complement activation, immune complex deposition, and leukocyte infiltration of target organs. Although the relative importance of these abnormalities may be different in various diseases, they do share common effector pathways, which may present attractive therapeutic targets. The commonly used wide-spectrum immunosuppressive and anti-inflammatory drugs such as systemic corticosteroids have clinical benefit, but are associated with significant side effects and do not induce long-lasting tolerance in humans. Their use is based mainly on empirical evidence of efficacy and not on the understanding of their mechanism of action on the immune system. Therefore, targeted interference with key components of inflammation provides the hope of more effective therapies.

Over the last decade we have seen remarkable progress in the development of targeted biologic therapies such as monoclonal antibodies and fusion proteins. Monoclonal antibody (mAb) technology was first discovered over three decades ago (Kohler and Milstein, 1975) and quickly revolutionized the management of malignancies, in the context of stem cell and solid organ transplantation, rheumatologic disorders, autoimmune disease, inflammatory bowel disease, infections and atopic disorders. Initially, mAbs were used as vehicles for transporting cytotoxic medications to the designated tissues; later, they were used to directly target molecules and cells of interest.

Currently available biologic therapies can be divided into those that target certain cell-surface molecules and those that interact with secreted molecules (Figure 1). Cell surface molecules can serve as markers specific for a particular cell, which can then be specifically targeted and deleted or manipulated by a mAb. For example, rituximab binds specifically to CD20, which is expressed on all B lymphocytes, except on very early precursor B cells and immunoglobulin-secreting plasma cells and leads to selective B cell depletion. Another class of molecules bind to cell surface proteins and interfere with their function without deleting or killing the cells. The most commonly used biologics interfere with the action of cytokines, which are soluble mediators of inflammation. Cytokines exert their action by binding to cell surface receptors. The action of cytokines can be blocked by binding the soluble cytokine or preventing its binding to its cognate receptor. The former can be achieved by using monoclonal antibodies against the cytokine or by using a decoy, soluble receptor, which will bind to the cytokines in a manner similar to that of cell surface receptors, thereby reducing the levels of free, biologically active cytokines. All of these options have already been successfully employed in the treatment of rheumatoid arthritis (RA). From three anti-tumor necrosis factor (TNF) agents approved in the United States, two (infliximab and adalimumab) are monoclonal antibodies, whereas etanercept is a soluble receptor fusion protein.

Figure 1.  Targets of biologic therapies: Mab, monoclonal antibody/biologic agent. (A) Biologic agent targeting membrane-bound molecules. Examples: anti-TNF (infliximab, adalimumab), anti-IL-6 receptor (tocilizumab), IL-1 receptor antagonist (anakinra), CTLA4 Ig (abatacept). (B) Biologic agent targeting soluble molecules. Examples: anti-TNF (infliximab, adalimumab), anti-BLyS (belimumab). TNF, tumor necrosis factor; IL, interleukin; CD, cluster of differentiation; BLyS, B lymphocyte stimulator

Although the interaction between these inhibitors and their targets is very specific, we are still learning about the diversity and complexity of their biologic mechanisms of action. They may have a direct effect on disease pathogenesis – for example through complement- and/or antibody-mediated destruction of cells and apoptosis or competitive inhibition of binding of molecules to their receptor. Alternatively, they may have an indirect effect – for example through sensitization of cells to conventional chemotherapy or down-regulation of receptors.

Specific therapies

Introduction on TNF/TNFRSFP

Tumor necrosis factor-α (TNF-α) belongs to the TNF/TNFR superfamily of proteins (TNFRSFP) which consists of structurally and functionally similar proteins. They are highly conserved and play important roles in innate immunity and host defenses, inflammation, apoptosis, lymphoid organ and tissue development, and homeostasis and organogenesis.

All of the TNF/TNFR proteins share the same basic homotrimer quaternary structure (Banner et al, 1993) with an elongated cystein-rich extracellular tail, transmembrane domain, and intracellular tail. While some members of the TNF receptor superfamily can signal for cell death, the majority do not have a death domain, and these receptors activate a wide variety of cellular functions such as lymphocyte costimulation, bone turnover, T-B cell interactions, and lymphocyte development and homeostasis.

The knowledge about the structure and function of TNF superfamily of cytokines, coupled with the invention of mAb technology, has revolutionized the treatment approach to many immune-mediated diseases in areas such as rheumatology, gastroenterology, and dermatology. Blocking TNF receptor-ligand interaction has proved very successful in treating diseases such as RA, juvenile idiopathic arthritis, cutaneous psoriasis, psoriatic arthritis, and Crohn’s disease. The list of indications for using this approach is rapidly expanding.

TNF-α

TNF-α is produced by stimulated myeloid cells. There are two TNF receptors, p55 (TNFR1) and p75 (TNFR2), that are widely expressed on most resting cells.

The role of TNF-α has been extensively studied in RA, which is a prototypic systemic deforming arthritis, affecting approximately 1% of the adult population. Studies on the pathogenic mechanisms of RA have revealed that TNF-α is a critical cytokine viewed as a ‘conductor’ in the inflammatory cascade (Choy and Panayi, 2001) that results in irreversible joint damage, bone and cartilage destruction (Bertolini et al, 1986; Saklatvala, 1986), significant morbidity and mortality (Pincus et al, 1984; Pincus and Callahan, 1986).

Tumor necrosis factor-α transgenic mice develop RA-like disease (Keffer et al, 1991). Treatment with TNFR2-Fc (Keffer et al, 1991) or a mAb against TNF (Williams et al, 1992) can ameliorate this phenotype.

Following these discoveries, a series of pivotal trials in patients with RA showed the therapeutic benefit of TNF blockade (Elliott et al, 1993, 1994, 1995). Subsequently, three biologic agents, engineered to block TNF action, have been approved by the Food and Drug Administration (FDA) for clinical use in the United States (Table 1). They have been shown to be effective in a growing number of inflammatory conditions, including RA, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.

Table 1.   Biologic agents used in rheumatology

	Target molecule	Generic name	Brand name	Mode of action	US FDA-labeled indications	Administration
TNF, tumor necrosis factor; AS, ankylosing spondyloarthropathy, RA, rheumatoid arthritis; PsA, psoriatic arthritis; BLyS, B lymphocyte stimulator; IL, interleukin; NHL, non-Hodgkin’s lymphoma; under clinical investigation, no US FDA-labeled indications at present.
Cell-surface molecular target	TNF-α	Infliximab	Remicade™	Inhibits TNF binding to its receptor	RA, PsA, AS, Crohn’s disease, Plaque psoriasis	i.v.
	TNF-α	Adalimumab	Humira™	Inhibits TNF binding to its receptor	RA, PsA, AS, Crohn’s disease	s.c.
	IL-1R	Anakinra	Kineret™	Inhibits IL-1 binding to its receptor	RA	s.c.
	IL-6R	Tocilizumab	MRA™, Actemra™	Inhibits IL-6 binding to its receptor	Under clinical investigation	i.v.
	CD20	Rituximab, ocrelizumab	Rituxan™, MabThera™	Depletes B cell	RA, NHL	i.v.
	CD22	Epratuzumab		Non-depleting B cell immune modulation	Under clinical investigation	i.v.
	CD25 (IL-2 receptor)	Daclizumab, basiliximab	Zenapax™, Simulect™	Inhibits IL-2 binding to its receptor	Renal transplant rejection	i.v.
	CD80, CD86	Abatacept	Orencia™	Inhibits co-stimulation of B cells	RA	i.v.
Soluble target	TNF-α, TNF-β	Etanercept	Enbrel™	Inhibits TNF binding to its receptor	RA, PsA, AS, JIA	s.c.
	TNF-α	Infliximab	Remicade™	Inhibits TNF binding to its receptor	RA, PsA, AS, Crohn’s disease, plaque psoriasis	i.v.
	TNF-α	Adalimumab	Humira™	Inhibits TNF binding to its receptor	RA, PsA, AS, Crohn’s disease,	s.c.
	BLyS	Belimumab	LymphoStat-B™	Inhibits B cell development	Under clinical investigation	i.v.

Etanercept (Enbrel™, Immunex, Seattle, Washington, USA), a TNF receptor p75 Fc fusion protein (TNFR:Fc), is a soluble recombinant form of the extracellular domain of human TNFR2 receptor fused to the Fc fragment of human immunoglobulin G1 (IgG1). It binds to soluble TNF and LT-α, effectively neutralizing the biologic activity of TNF.

Etanercept, alone or in combination with methotrexate, has been shown to be effective in patients with early and long-standing RA in randomized, double-blind, placebo-controlled clinical trials (Moreland et al, 1997; Weinblatt et al, 1999; Bathon et al, 2000) with sustained response over 2 years (Genovese et al, 2002). It is also approved for treatment of polyarticular juvenile RA (Lovell et al, 2000), plaque psoriasis, active psoriatic arthritis in adults, and for treatment of adult patients with chronic moderate to severe plaque psoriasis (Mease et al, 2000) as well as active ankylosing spondylitis (Gorman et al, 2002). The usual dose of etanercept is 25 mg for adults and 0.4 mg kg⁻¹ for children twice a week subcutaneous injections for treatment of RA, psoriatic arthritis, and ankylosing spondylitis. Comparable clinical benefit in adults with RA has been demonstrated with a once-weekly injection of 50 mg (Keystone et al, 2004a,b).

Infliximab (Remicade™, Centocor, Inc., Malvern, Pennsylvania, USA), is a chimeric mAb composed of the antigen-binding region of a mouse anti-TNF monoclonal antibody and the constant region of human IgG1 (Winterfield and Menter, 2004). It binds to both soluble and transmembrane TNF-α with high affinity (Targan et al, 1997). Infliximab is approved for use in patients with RA who have had an inadequate response to methotrexate alone (Lipsky et al, 2000). The combination of infliximab and methotrexate was superior in reducing signs and symptoms and slowing the progression of joint damage in patients with active (Lipsky et al, 2000) and early (St Clair et al, 2004) RA compared with methotrexate alone, with efficacy sustained for up to 2 years (Maini et al, 2004).

Other indications of infliximab use include ankylosing spondylitis, moderate-to-severe active Crohn’s disease with draining enterocutaneous fistulas (van Dullemen et al, 1995; Van Deventer, 1997; Present et al, 1999), and treatment-refractory ulcerative colitis.

Another monoclonal antibody against TNF-α is adalimumab (Humira™, Abbott Laboratories, North Chicago, Illinois, USA). It is a recombinant, fully humanized IgG1 anti-TNF-α monoclonal antibody with low immunogenicity. It has been FDA approved for moderate-to-severe RA (Furst et al, 2003; Weinblatt et al, 2003; Weisman et al, 2003; Keystone et al, 2004a,b), psoriatic arthritis, moderate-to-severe Crohn’s disease, and ankylosing spondilitis. The recommended dose is 40 mg subcutaneously every 2 weeks alone or concomitantly with methotrexate.

The safety profile of anti-TNF biologics has become an area of active post-marketing evaluation because of concerns of potential adverse events some of which were not documented during the clinical trials phase, such as infections, malignancies and lymphoma, demyelinating disorders, aplastic anemia, congestive heart failure, and vasculitis (Mohan et al, 2004; Richette et al, 2004). These concerns were addressed by the FDA Arthritis Advisory Committee http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm. Injection site reaction has been the most commonly reported adverse reaction with the subcutaneously administered drugs (20–40%) (Moreland et al, 1999). Hypersensitivity reaction associated with infliximab is more rare, although more serious (Maini et al, 1999).

Patients treated with anti-TNF medications are at increased risk of conventional bacterial and opportunistic infections (Warris et al, 2001; Helbling et al, 2002; Kamath et al, 2002; Lee et al, 2002; Nakelchik and Mangino, 2002). Oral and esophageal candidiasis in patients treated with anti-TNF agents can be rarely seen in dental practice (Ricart et al, 2001). The risk of serious and life-threatening infections is also increased (Bongartz et al, 2006). Reactivation of latent tuberculosis is a particular complication that usually develops within the first few months of therapy, presenting as atypical extrapulmonary and miliary disease. For that reason screening for latent tuberculous infection is strongly recommended prior to initiation of any TNF-blocking agents.

Immunogenicity has been observed during anti-TNF therapy with the development of ANA and anti-double-stranded DNA (anti-dsDNA) antibodies of IgM isotype, but their clinical significance is still a matter of debate. Adding methotrexate to the regimen reduces the incidence of these and other antibodies.

Additional areas of concern are potentially demyelinating syndromes (Mohan et al, 2001) and increased morbidity and mortality in patients with congestive heart failure while on anti-TNF medications.

Malignancy and lymphoma have been documented in RA patients treated with TNF blockers in clinical trials (Bongartz et al, 2006). However, patients with RA have an increased risk of lymphoproliferative diseases and non-Hodgkin’s lymphoma in particular (standardized incidence ratio: 2.4–8.9) (Isomaki et al, 1978; Matteson et al, 1991; Gridley et al, 1993; Baecklund et al, 1998), based on epidemiological studies from pre-biologics era. All these facts complicate the interpretation of the post-marketing data trying to link the use of anti-TNF agents and lymphoma, and the debate is still open.

Anti-TNF biologics in oral medicine: Sjögren’s syndrome

Sjögren’s syndrome is a common inflammatory condition (prevalence 0.5–4%) (Thomas et al, 1998) associated with dry mouth and dry eyes resulting from chronic exocrine hypofunction. As a consequence, patients develop a multitude of oral and dental complications such as oral candidiasis and root and incisal caries with tooth erosion in some cases (Atkinson and Fox, 1993), which are inversely proportional to the salivary flow. Studies in mouse models of Sjögren’s syndrome suggest that TNF plays an important role in the pathogenesis of the disease, and TNF blockade may prevent the associated salivary inflammation (Tornwall et al, 1999). This notion was supported by studies in rabbit models of the disease (Zhu et al, 2003) and in vitro studies with immortalized human salivary acinar cells (Azuma et al, 2002). Following these discoveries, a series of quality randomized clinical trials in humans using different anti-TNF agents were conducted. They showed improvement in rheumatologic signs and symptoms, such as arthritis, but failed to demonstrate benefit to the sicca symptoms (Mariette et al, 2004; Sankar et al, 2004). In addition, patients with primary Sjögren’s syndrome are at 16- to 44-fold increased risk of developing non-Hodgkin’s lymphoma estimated from epidemiologic studies (Kassan et al, 1978; Lazarus et al, 2006; Theander et al, 2006). This consideration coupled with the lack of efficacy on the sicca manifestations may have significant implications in this patient population where the indications for administering anti-TNF biologics should be carefully weighed.

Interleukin-1 (IL-1)

Interleukin-1 is another cytokine important in the propagation of inflammation via induction of IL-6 and cyclooxygenase-2 (Dinarello, 1996). It plays a critical role in the pathogenesis of RA (Horai et al, 2000; Choy and Panayi, 2001) and other rheumatic diseases. Its natural inhibitor, IL-1 receptor antagonist (IL-1Ra), blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to its receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. This mechanism was used to develop a recombinant IL-1Ra biologic agent (anakinra; Kineret™, Amgen, Inc., Thousand Oaks, California, USA). In randomized clinical trials, daily injections of anakinra have been shown to reduce the signs and symptoms of RA and radiographic progression of disease (Cohen et al, 2002). This led to FDA approval of anakinra for treatment of RA but its specific place in the RA therapeutics armamentarium remains to be defined (Furst et al, 2007). The combination of anakinra with methotrexate and other non–anti-TNF disease-modifying anti-rheumatic drugs (DMARDs) is well tolerated (Cohen et al, 2002), but the combination with etanercept was associated with a significant increase in adverse events and serious infections, and is not recommended (Fleishmann, 2002; Genovese et al, 2004). The most frequent side effect is injection site reaction followed by infections. There is no indication that anakinra is associated with increased incidence of tuberculosis.

Anankinra has been found to be very effective in treating neonatal onset multisystem inflammatory disease and other rheumatic diseases where the innate immune system is activated (Goldbach-Mansky et al, 2006; Kalliolias et al, 2007).

One study found IL-1R antagonist polymorphism in patients with Sjögren’s syndrome, suggesting a potential application of anakinra in this patient population (Perrier et al, 1998), but experience with this drug in Sjögren’s syndrome is lacking.

Interleukin-6 (IL-6)

Interleukin-6 is a pleiotropic cytokine with a wide range of biologic activities (Choy and Panayi, 2001; Naka et al, 2002). IL-6 plays an important role in the regulation of immunologic reactions, inflammation, acute phase responses, and hematopoiesis. One of the most important biologic actions of IL-6 is its ability to stimulate the final stages of B-lymphocyte maturation. Under the influence of IL-6, B-lymphocytes differentiate into mature plasma cells and become immunoglobulin-secreting cells. In addition, IL-6 induces T-cell growth and cytotoxic T-cell differentiation through augmentation of IL-2 receptor expression and IL-2 production.

Overproduction of IL-6 is pathologically involved in some autoimmune diseases, such as RA (Hirano et al, 1988; Madhok et al, 1993), systemic-onset juvenile idiopathic arthritis (De Benedetti et al, 1994), Sjögren’s syndrome (Boras et al, 2004), and systemic lupus erythematosus (SLE) (Linker-Israeli et al, 1991; Peterson et al, 1996; Grondal et al, 2000; Tackey et al, 2004). Elevated serum levels of IL-6 are responsible for systemic inflammatory manifestations, such as general fatigue, fever, anemia, increases in acute phase proteins including serum amyloid A, C-reactive protein (CRP) and fibrinogen, and immunologic disorders including polyclonal hyper-γ-globulinemia and production of autoantibodies, all hallmarks of systemic rheumatic diseases.

Anti-IL-6 receptor monoclonal antibody, tocilizumab

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody which is in advanced clinical trials for adult and juvenile RA. Several large phase II studies have demonstrated the efficacy of tocilizumab in RA both as monotherapy and in combination with methotrexate (Nishimoto et al, 2004, 2007; Nishimoto, 2006). Responses were highest in subjects treated with methotrexate and 8 mg kg⁻¹ tocilizumab every 4 weeks with about 75% of patients achieving an ACR20 response (Maini et al, 2006). Another study also reported significant radiographic benefit (Nishimoto et al, 2007) Tocilizumab is generally well tolerated. Serum cholesterol levels increased in 44.0% of the patients. Liver function disorders and decreases in white blood cell counts were also observed, but these were mild and transient. This therapy may be a promising treatment for RA. In terms of systemic juvenile idiopathic arthritis patients with tocilizumab, the clinical symptoms were improved and the elevated levels of acute-phase reactants were normalized (Woo et al, 2005; Yokota et al, 2005).

CTLA4 and the concept of co-stimulation (‘two signal’ model)

Bretscher and Cohn (1970) first proposed the ‘two signal’ model for lymphocyte activation. The hypothesis, originally put forth for B lymphocyte activation and later also adopted for T lymphocyte activation, stated that occupation of the antigen-specific receptor on the naïve lymphocyte surface was not sufficient to activate that cell. Instead, naïve B or T lymphocyte activation requires one antigen-specific signal through its antigen receptor (B or T cell receptor, respectively), and another non-antigen-specific ‘costimulatory’ signal from the antigen-presenting cell (APC) through receptors, such as CD40 or CD28. In the absence of costimulation through the second signaling pathway, T cells not only do not become active, but may even die or become unresponsive, i.e. anergic. Interfering with the second signal and signaling pathway has a natural regulatory role and has been shown to have a potent effect on inducing immune tolerance in experimental settings. During a normal immune response activated T cells express a molecule named cytotoxic T cell-associated antigen 4 (CTLA4), which binds to CD86 with a much higher affinity than CD28. This inhibitory effect prevents the ability of CD86:CD28 interaction to perpetuate further inflammation and tissue damage (Bluestone et al, 2006).

CTLA4 Ig, abatacept

The knowledge of the ‘two signal’ model has led to the generation of the first CD28 costimulation antagonist, called CTLA4 Ig (Bluestone et al, 2006) (abatacept; Orencia™, Bristol-Myers Squibb Co., Princeton, New Jersey, USA), a soluble fusion protein, consisting of the extracellular domain of human CTLA4 and a fragment of the Fc domain of human IgG1. It has been used to treat successfully several animal models of autoimmunity, including murine lupus (Davidson et al, 2005), diabetes in non-obese diabetic mice (Lenschow et al, 1995), collagen-induced arthritis (Brookes et al, 1996), and experimental autoimmune encephalomyelitis (Khoury et al, 1995). It was also vigorously studied in randomized clinical trials in patients with RA and demonstrated significant clinical and functional benefit in patients who had inadequate response to anti-TNF therapy (Genovese et al, 2005) or methotrexate (Kremer et al, 2003, 2006). Following these pivotal trials, abatacept was FDA approved in 2006 for the treatment of moderate-to-severe RA refractory to other DMARDs. Abatacept was recently reported to have sustained effect on inhibiting radiographic progression in a 2-year extension follow-up study (Genant et al, 2007). A combination of abatacept with etanercept in patients with active RA has however been associated with increased incidence of serious adverse events, including infections and should be avoided (Weinblatt et al, 2007).

To date, this medication has not been studied in Sjögren’s syndrome and its effects on oral health are largely unknown, even though a recent study reported on the significance of CTLA4 haplotype/phenotype association (Downie-Doyle et al, 2006) in Sjögren’s syndrome, suggesting that it may be an attractive therapeutic target.

A similar CD28 costimulation antagonist, belatacept, is being investigated as immunosuppressive medication in renal transplantation (Vincenti and Luggen, 2007).

B-cell-targeted therapies

B lymphocytes play an important role in the pathogenesis of autoimmune diseases, including SLE, RA, and Sjögren’s syndrome. B lymphocytes are not only the precursors of immunoglobulin-secreting plasma cells, but are effective APC (especially of autoantigens) and modulate the function of other immune cells through the production of cytokines. B cell hyperactivity is a dominant feature of many autoimmune diseases and, unlike in normal individuals, B cells from SLE and Sjögren’s syndrome patients spontaneously produce large amounts of immunoglobulins. Moreover, in Sjögren’s syndrome, 5–8% of the patients may develop malignant B-cell lymphoma, usually of the mucosa-associated lymphoid tissue type which is most frequently located in the major salivary glands. B cell depletion by targeting B cell-specific antigens, such as CD20 and CD22, has recently emerged as an attractive way of controlling autoimmunity.

Anti-CD20, rituximab

Rituximab (Rituxan™, Genentech, South San Francisco, California, USA) is a chimeric mouse-human monoclonal antibody against the B cell-specific antigen CD20, which selectively and profoundly depletes CD20-positive B lymphocytes via complement-mediated and antibody-dependent cell-mediated cytotoxicity, induction of apoptosis, and inhibition of cell growth (Reff et al, 1994). It has been successfully used and FDA approved for treatment of patients with non-Hodgkin’s B cell lymphoma since 1997 with minimal toxicity. Since then it has been reported to be effective in cases and case series of patients with concomitant RA or RA alone (Leandro et al, 2002). These reports have led to the development of several randomized, clinical trials of rituximab for treatment-refractory RA (Edwards et al, 2004; Cohen et al, 2006; Emery et al, 2006) that demonstrated its efficacy and safety either alone or in combination with methotrexate or cyclophosphamide. This resulted in FDA approval of rituximab for moderate-to-severe RA in subjects who had inadequate response to anti-TNF therapy.

Depleting B cells using rituximab in patients with active SLE has also been shown to be beneficial (Leandro et al, 2005; Smith et al, 2006; Thatayatikom and White, 2006). Outcomes of phase I/II studies also demonstrated improvement in B cell homeostasis and self-tolerance after B cell depletion with rituximab (Anolik et al, 2004).

The adverse events with rituximab are mild to moderate transfusion reactions and hypogammaglobulinemia. However, the levels did not fall below the normal range (Looney et al, 2004). Rituximab-specific human anti-chimeric antibodies (HACA) develop in up to 27% of patients and in some cases are associated with serum sickness-like disorder (Pijpe et al, 2005). Infections, including opportunistic infections such as JC virus-associated progressive multifocal leukoencephalopathy, have been reported (http://www.fda.gov/cder/drug/InfoSheets/HCP/rituximab.pdf).

Aa B cells have been shown to play an important role in Sjögren’s syndrome pathogenesis, they have become attractive therapeutic targets in this disease. To date, three relatively small open-label studies have demonstrated the utility of rituximab in this patient population (Gottenberg et al, 2005a,b; Pijpe et al, 2005; Seror et al, 2007). As a whole they reported improvement in extraglandular manifestations, glandular swelling, and subjective symptoms of dryness. The data on objective salivary and lacrimal function however have been inconsistent. These results justified the development of two European randomized controlled trials designed to evaluate the safety and efficacy of rituximab in patients with primary Sjögren’s syndrome that are currently recruiting patients (http://www.clinicaltrials.gov, NCT00363350 and NCT00426543).

Anti-CD22, epratuzumab

CD22 is a B-lymphocyte-restricted member of the immunoglobulin superfamily, and a member of the sialoadhesin family of adhesion molecules that regulate B cell activation and interaction with T cells (Kelm et al, 1994; Tedder et al, 1997). CD22 plays a key role in B cell development and survival because CD22-deficient mice have reduced numbers of mature B cells in the bone marrow and circulation, and the B cells also have a shorter lifespan and enhanced apoptosis (Otipoby et al, 1996). As dysregulated expression of CD22 could lead to excessive activation of B cells and autoantibody production (O’Keefe et al, 1999), targeting this co-receptor in systemic autoimmunity appears to be a potentially new therapeutic pathway. In 16 patients with active pSS, the open-label, phase I/II study of epratuzumab, a humanized anti-CD22 monoclonal antibody, was reported (Steinfeld et al, 2006). A composite end-point involving the Schirmer-I test, unstimulated salivary flow, fatigue, erythrocyte sedimentation rate and immunoglobulin-G (IgG) was devised to provide a clinically meaningful assessment of response. Approximately 40–50% responded at the >30% level, while 10–45% responded at the >50% level for 10–32 weeks. Additionally, statistically significant improvements were observed in fatigue. Fourteen patients received all infusions without significant reactions, one patient received three, and another was discontinued after receiving a partial infusion due to a mild acute reaction. Three patients showed moderately elevated levels of HAHA (human anti-human/epratuzumab antibodies) not associated with clinical manifestations. Primary SS patients have CD22 over-expression on peripheral B cells which was down-regulated by epratuzumab therapy. B-cell levels had moderate reductions, but T-cell levels, immunoglobulins, and routine safety laboratory tests did not change significantly. Thus, epratuzumab appears to be a promising therapy in active pSS. In a phase II study in mild to moderate SLE 14 patients, Dorner et al (2006) demonstrated that the therapy was well tolerated, with consistent improvement observed in almost all patients in the presence of modestly decreased peripheral B cell levels without human anti-epratuzumab antibody titers and without significant adverse events. A multicenter study is being conducted to further assess the long-term safety and efficacy of epratuzumab in patients with SLE (http://www.clinicaltrials.gov, NCT00383513).

BLyS (B-Lymphocyte stimulator)

B-lymphocyte stimulator or BLyS (also known as BAFF, TALL-1, THANK, TNFSF20, and zTNF4) is a 285-amino acid member of the TNF superfamily of cytokines. It is expressed on macrophages and other APC, and is a vital B cell survival factor, inducing B cell differentiation, proliferation, and Ig secretion.

A number of studies have found elevated levels of serum BLyS in patients with SLE and these levels correlate with disease activity and levels of anti-dsDNA auto-antibodies and Ig (Zhang et al, 2001). In patients with primary Sjogren’s syndrome, BLyS is upregulated in the serum and salivary tissue (Lavie et al, 2004; Gottenberg et al, 2005a,b), correlates with serum auto-antibody levels of IgG, RF, anti-SSA and anti-SSB (Mariette et al, 2003), and has been implicated in the pathogenesis of the disease (Groom et al, 2002).

Anti-BLyS monoclonal antibody, belimumab

Targeting the BLyS molecule with an anti-BLyS monoclonal antibody has proved safe and well tolerated in phase I clinical trials in lupus (Dorner et al, 2006) and neutralization of serum BLyS correlated with clinical improvement of the disease. A phase III international randomized clinical trial is currently recruiting patients with active SLE to evaluate the safety and efficacy of belimumab (http://www.clinicaltrials.gov, NCT00410384).

Based on the preclinical data and the experience with anti-BLyS in other diseases, one can reason that this medication should be studied systematically as a treatment option in Sjögren’s syndrome.

Other biologic targets

Cytokines mediate a wide variety of biologic activities that are relevant to autoimmune diseases including immune response, inflammation, and tissue repair and remodeling. Restoring the optimal cytokine balance may have therapeutic value and theoretically can be achieved either by blocking inflammatory cytokines or inducing or providing anti-inflammatory ones.

α-Interferon

α-Interferon (IFN-α) has been suggested to play an important role in the pathogenesis of several rheumatic diseases including SLE and Sjögren’s syndrome (Bave et al, 2005; Borg and Isenberg, 2007). This suggests that IFN-α may be used as a therapeutic target and interfering with its activity may result in amelioration of chronic inflammation.

In several phase II studies low-dose natural human IFN-α administered through the oral mucosal route improved salivary output and decreased complaints of xerostomia in patients with primary Sjögren’s syndrome (Shiozawa et al, 1993, 1998; Ferraccioli et al, 1996; Ship et al, 1999; Khurshudian, 2003). However, in a phase III study, although IFN-α increased unstimulated whole saliva flow significantly more than placebo, the co-primary end-points of stimulated whole saliva flow and oral dryness were not significantly improved in the IFN-α group relative to placebo (Cummins et al, 2003).

Conclusions and future directions

Past decades have led to much improved understanding of many diseases and the development of specific treatments. As promising as these new therapeutic approaches are, there are also considerations in weighing the benefit-to-risk ratio. As most of these medications have been on the market for less than a decade, the long-term toxicity profile is not known. Cost is also a limiting factor as some of these treatments run to thousands of USD per year and most of them are being used as chronic therapies.

Despite recent advances, there is an urgent need for cost-effective innovative therapies with improved toxicity profile and curative potential. A trend toward more rational drug design has been documented in a recent study (Yildirim et al, 2007). Scientists have been studying the applicability of fragments of antibodies (Check, 2007). Oral, rather than injectable, modes of delivering these molecules are being actively explored. New approaches using stem cell transplantation, both autologous and allogeneic, are currently under intensive investigation. Some immunomodulatory properties of mesenchymal stem cells make them attractive candidates for cell-based therapies and open new avenues for future research (Tyndall et al, 2007).

Acknowledgements

We would like to thank Ilias Alevizos, DMD, and Jaime Brahim, DDS, for their critical review and suggestions on the manuscript.

Author contributions

Gabor Illei, Nikolay P. Nikolov and Youko Shirota participated in the generation and drafting of the manuscript.